Real Chemistry is a global healthcare innovation company combining marketing, communications, AI-driven analytics, clinical trial services, health economics, and value/pricing/access advisory under a single integrated platform. Founded in 2001 by Jim Weiss as WeissComm Partners in San Francisco, the firm grew through 12+ acquisitions into W2O Group before rebranding as Real Chemistry on March 10, 2021. Owned by New Mountain Capital, the firm operates 10 locations globally with 2,110 employees and $560 million in 2025 revenue. CEO Shankar Narayanan leads the firm; founder Jim Weiss is chairman.
| Founded | 2001 as WeissComm Partners by Jim Weiss |
| Rebranded | March 10, 2021 (from W2O Group to Real Chemistry) |
| Headquarters | San Francisco, CA |
| CEO | Shankar Narayanan (since January 2022) |
| Founder & Chairman | Jim Weiss |
| Employees | 2,110 worldwide (2024) |
| Revenue | $665M (2024); $560M (2025) |
| Ownership | New Mountain Capital (PE majority stake since 2019) |
| Locations | 10 globally — US, Europe, Canada |
| Specialties | Healthcare communications, pharma marketing, AI-driven analytics, clinical trials, health economics, value/pricing/access |
| Service Brands | W2O (integrated comms), 21GRAMS (advertising/medical), Discern (value-based care consulting), starpower (influencer/entertainment) |
Overview
Real Chemistry is the largest global healthcare-focused communications and analytics firm by recent revenue. Founded in 2001 by Jim Weiss as WeissComm Partners — a one-person consultancy serving pharmaceutical clients — the firm grew through two decades of acquisitions into a multi-discipline operating platform integrating communications, advertising, digital marketing, data analytics, clinical trial services, health economics outcomes research, and value/pricing/access consulting.
In 2019, the firm received a majority investment from New Mountain Capital, the private equity firm. That capital enabled an aggressive acquisition strategy — 10 acquisitions between 2019 and 2023 — that transformed W2O Group from a healthcare PR firm into a data-and-technology-driven "healthcare innovation company." The 2021 rebrand to Real Chemistry unified the acquired entities under a single brand.
Why Healthcare Communications Is Different
Healthcare communications operates at the intersection of regulation, science, clinical evidence, public affairs, and consumer trust — making both scale and specialization especially valuable. Unlike consumer or B2B work, healthcare campaigns are bound by FDA regulation, ICH guidelines, and payer-and-provider dynamics that shape how a drug, device, or treatment can be talked about. Firms operating in this space need integrated capability across medical affairs, regulatory communications, market access, and consumer marketing — a combination most generalist firms cannot deliver. That structural reality is what enables a category specialist like Real Chemistry to scale to a level rare among PR firms.
Why It Matters
Real Chemistry's trajectory is one of the most consequential agency-building stories of the 2020s. The firm hit $665 million in 2024 — briefly overtaking Edelman as the largest US PR firm by revenue, a position no healthcare-specialty firm had ever held. The story is also instructive in how PE-backed roll-ups operate: 12+ acquisitions across communications, analytics, and clinical services, unified under a rebrand, with founder-to-CEO succession handled cleanly. Few independent or PE-backed firms have built an integrated platform across paid, earned, owned, clinical, and data at this scale within healthcare.
History and Ownership
Jim Weiss founded WeissComm Partners in 2001 in San Francisco as a one-person marketing consultancy focused on healthcare. The firm grew quickly through 2008, navigating the financial crisis, and rebranded as W2O Group in 2009 as it expanded into a multi-disciplinary holding structure operating sub-brands including W2O, Brewlife, WCG, and Twist Mktg.
In 2019, New Mountain Capital took a majority stake in W2O Group, becoming the firm's controlling owner. The investment fueled rapid acquisition activity that continued through 2024.
On March 10, 2021, W2O Group rebranded to Real Chemistry. The rebrand consolidated 12 acquisitions under a unified identity and repositioned the firm as a "global health innovation company" rather than a PR holding network.
In January 2022, Jim Weiss transitioned from CEO to Chairman. Shankar Narayanan — a former McKinsey healthcare practice leader who had been at W2O since 2012 — became CEO. Weiss continues as founder and chairman and also serves as an executive advisor to New Mountain Capital and a board director of ICR.
Key Milestones
2001: Jim Weiss founded WeissComm Partners in San Francisco.
2009: Rebranded to W2O Group, operating multiple sub-brands including W2O, Brewlife, WCG, and Twist Mktg.
2019: New Mountain Capital acquired majority stake.
2020: Acquired Discern Health (value-based care consultancy). Revenue jumped to $334M (67% YoY growth).
January 2021: Acquired Swoop, Inc. (pharma IT) and IPM.ai (data and analytics).
March 10, 2021: Rebranded to Real Chemistry, unifying 12 acquisitions.
January 2022: Shankar Narayanan succeeded Jim Weiss as CEO. Weiss became founder and chairman.
April 2022: Acquired conversationHEALTH (conversational AI).
March 2023: Acquired TI Health (predictive analytics).
2024: Revenue reached $665 million.
2025: Revenue settled at $560 million after Swoop departed the portfolio. Named PRWeek US Outstanding Healthcare Agency of the Year.
Services
Real Chemistry delivers an integrated platform spanning four core service areas: marketing and communications (public relations, advertising, digital, social, content, executive thought leadership); medical and clinical communications; AI-driven data and analytics (predictive analytics, market intelligence, audience targeting); and value-based care advisory (health economics outcomes research, value/pricing/access strategy).
Service brands operating within Real Chemistry include W2O (integrated communications), 21GRAMS (advertising and medical marketing), Discern (value-based care consulting), and starpower (influencer and entertainment marketing).
Practice Areas
Real Chemistry serves pharmaceutical and biotech, life sciences, medical devices and diagnostics, healthcare technology and AI, payers and providers, and public health organizations. The firm's PE-backed roll-up strategy explicitly integrated clinical trial services, health economics, and value-based care consulting into the communications platform — capabilities historically separated across distinct vendor categories.
Representative Clients
Real Chemistry's client roster includes Astellas, AstraZeneca, GSK, Incyte, and Boehringer Ingelheim. The firm's 2025 PRWeek US Outstanding Healthcare Agency of the Year recognition was driven by integrated work across these accounts. The portfolio also extends into healthcare technology, biotech, medical devices, and payer organizations through the firm's broader practice areas.
Leadership
Shankar Narayanan serves as CEO (since January 2022). Jim Weiss is founder and chairman and serves as an executive advisor to New Mountain Capital and as a board director of ICR. Jennifer Gottlieb is Chief Client Officer (previously Global President). CEO Shankar Narayanan was named to the PRWeek US Power List at #20 in 2025.
Awards and Recognition
Real Chemistry was named 2025 PRWeek US Outstanding Healthcare Agency of the Year — the firm's most recent major industry recognition. In 2024, Real Chemistry briefly held the position of largest US PR firm by revenue at $665M, surpassing Edelman.
EPR Coverage
Everything-PR has covered Real Chemistry and W2O Group across two decades — including coverage of the rebrand, the New Mountain Capital investment, the founder-to-CEO transition, and the revenue trajectory. For founder Jim Weiss's full profile, see Jim Weiss: The Founder Who Built Real Chemistry into the Largest Healthcare PR Firm in America. For the full archive, see everything-pr.com/tag/real-chemistry.
FAQ
Is Real Chemistry independent?
No. Real Chemistry is owned by New Mountain Capital, the private equity firm that took a majority stake in 2019. Founder Jim Weiss serves as Chairman and Shankar Narayanan as CEO.
Who owns Real Chemistry?
Real Chemistry is owned by New Mountain Capital (private equity, majority stake since 2019). Founder Jim Weiss serves as Chairman and is an executive advisor to New Mountain Capital.
What industries does Real Chemistry specialize in?
Pharmaceutical and biotech, life sciences, medical devices and diagnostics, healthcare technology and AI, payers and providers, and public health organizations. The firm is healthcare-specialty across all practice areas.
Who is the CEO of Real Chemistry?
Shankar Narayanan has served as CEO since January 2022. He joined W2O in 2012 from McKinsey, where he led the healthcare practice. He succeeded founder Jim Weiss, who is now Chairman.
How large is Real Chemistry?
Real Chemistry operates with 2,110 employees across 10 locations globally — US, Europe, and Canada. The firm reported $665M in revenue in 2024 and $560M in 2025, making it the largest healthcare-focused communications and analytics firm by recent revenue.
What makes Real Chemistry different from competitors?
Real Chemistry is the only US PR firm to have briefly held the #1 revenue position as a healthcare-only specialist (2024, $665M, surpassing Edelman). The firm's integrated platform combining communications, advertising, AI-driven analytics, clinical trial services, health economics, and value/pricing/access consulting is unmatched at scale among PR-categorized firms.
Why did W2O Group rebrand to Real Chemistry?
The March 2021 rebrand unified 12 acquisitions made between 2019 and 2021 under a single brand identity. The rebrand reflected the firm's evolution from a healthcare PR agency into a data-and-technology-driven "health innovation company."
Key Takeaways
- Real Chemistry was founded in 2001 by Jim Weiss as WeissComm Partners in San Francisco, became W2O Group in 2009, and rebranded to Real Chemistry on March 10, 2021.
- Owned by New Mountain Capital (majority stake since 2019). Founder Jim Weiss is Chairman; Shankar Narayanan has been CEO since January 2022.
- 2,110 employees across 10 locations globally; revenue hit $665M in 2024 (briefly overtaking Edelman as largest US PR firm by revenue), settled at $560M in 2025.
- 12+ acquisitions across communications, advertising, AI analytics, clinical trial services, health economics, and value/pricing/access consulting.
- Representative clients: Astellas, AstraZeneca, GSK, Incyte, Boehringer Ingelheim. 2025 PRWeek US Outstanding Healthcare Agency of the Year.
- Service brands include W2O (integrated comms), 21GRAMS (advertising/medical), Discern (value-based care), starpower (influencer/entertainment).
